Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 15, Issue 3 (May 2013) 15, 328–332; 10.1038/aja.2013.7

Neuroendocrine differentiation of prostate cancer

Zhen Li, Clark J Chen, Jason K Wang, Elaine Hsia, Wei Li, Jill Squires, Yin Sun and Jiaoti Huang

Departments of Pathology and Urology, Jonsson Comprehensive Cancer Center and Broad Center for Regenerative Medicine and Stem Cell Research, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095–1732, USA

Correspondence: Dr J Huang, (JiaotiHuang@mednet.ucla.edu)

Received 30 November 2012; Revised 8 January 2013; Accepted 9 January 2013; Advance online publication 18 March 2013

Abstract

Benign prostate and prostatic adenocarcinoma contain rare quiescent neuroendocrine cells while small cell neuroendocrine carcinoma (SCNC), a variant form of prostate cancer, contains highly proliferative neuroendocrine tumor cells. We provide evidence that IL-8-CXCR2-P53 pathway keeps the NE cells in a quiescent state normally. P53 mutation inactivates this pathway, resulting in hyper-proliferation and aggressive behavior of the NE cells in SCNC. Therefore, we have identified potential cells of origin and a molecular target for prostatic SCNC that are different from those of adenocarcinoma, which explains SCNC′s distinct biology and the clinical observation that it does not respond to hormonal therapy.

PDF | 中文摘要 |

 
Browse:  1162
Copyright 1999-2014    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved